HCA Holdings Inc (HCA), National-Oilwell Varco, Inc. (NOV) & Six Other Stocks Larry Robbins Says He Likes

With the “Alpha Delivering Conference” taking place today, the eyes and ears are turned towards some of the greatest asset management personalities who are presenting their insights. One of the speakers at the conference is Larry Robbins, the manager of Glenview Capital. Mr. Robbins has discussed most of the top holdings that can be seen in Glenview’s latest equity portfolio, including plays like Thermo Fisher Scientific Inc. (NYSE:TMO)Monsanto Company (NYSE:MON)Hertz Global Holdings, Inc. (NYSE:HTZ),  Flextronics International Ltd. (NASDAQ:FLEX), HCA Holdings Inc (NYSE:HCA) and one company in which Glenview has not yet disclosed a stake: National-Oilwell Varco, Inc. (NYSE:NOV).

GLENVIEW CAPITAL

The last two companies are worth mentioning for several reasons. HCA Holdings Inc (NYSE:HCA) has gone through a significant boost on Wednesday, the stock jumping by over 9.40%, while over the past year, it surged by over 55%. Also today the company has updated its guidance, expecting adjusted EPS between $4.00-$4.25, versus the previous guidance of $3.45-3.75. Aside from Glenview, which reported ownership of 12.84 million shares of HCA Holdings Inc (NYSE:HCA) as of the end of March, David Tepper’s Appaloosa Management Lp held around 5.33 million shares.

National-Oilwell Varco, Inc. (NYSE:NOV) has been up by 1.40% in today’s trading session. Warren Buffett’s Berkshire Hathaway is a shareholder of National-Oilwell Varco, Inc. (NYSE:NOV), holding around 8.8 million shares as of the end of March.

According to CNBC, Robbinson said that he likes these six stocks because the companies are able to take debt at low interest rates and engage in various activities that bring more value to shareholders, such as buying back shares.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!